Amgen sales rose by 5% in Q1

Share this article:

First-quarter Kyprolis sales of $68 million helped increase Amgen's first-quarter sales by 5% compared to the same period last year.

While the biotech saw increased demand and sales for drugs, including bone biologic Prolia and anemia product Epogen, demand and sales declined for some brands, with sales of RA shot Enbrel slipping 5% and kidney drug Aranesp sales falling 2% compared to the same period last year. The company attributed some of this fall-off to inventory draw-down.

Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Business Briefs

Email Newsletters

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Business Briefs

Monday Moves: September 15

Hires and promotions for manufacturers, regulatory and agencies

Kantar acquires Evidências, expands Brazilian presence

The company's acquisition signals the growing importance of understanding the Brazilian healthcare market and evidence-based healthcare management services.

Study says statins not enough for diabetic hearts

Researchers using an experimental test have discovered that the 50% of surveyed diabetics may also have undetected heart muscle damage.